We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
153 hedge funds and large institutions have $336M invested in Esperion Therapeutics in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 47 increasing their positions, 29 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
135% more call options, than puts
Call options by funds: $8.22M | Put options by funds: $3.49M
105% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 21
62% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 29
54% more capital invested
Capital invested by funds: $219M → $336M (+$118M)
16% more funds holding
Funds holding: 132 → 153 (+21)
3.58% more ownership
Funds ownership: 64.23% → 67.81% (+3.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
153
Holders Change
+21
Holders Change %
+15.91%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
43
Increased
47
Reduced
29
Closed
21
Calls
$8.22M
Puts
$3.49M
Net Calls
+$4.72M
Net Calls Change
-$3.15M
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$33.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$19.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$18.5M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$13.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$10.6M |
